Ascendis Pharma Earnings Call Highlights Growth Momentum
Ascendis Pharma A/S ((ASND)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma’s latest earnings call struck an upbeat tone, with management emphasizing rapid commercial growth, expanding global reach, and advancing late-stage assets. While high operating expenses, currency drags, and noncash finance hits weighed on reported profits, executives argued that cash generation and pipeline momentum set up a stronger long‑term value story.
Yorvipath revenue surge and broadening access
Yorvipath remained the star performer, with Q4 2025 revenue jumping 33.6% quarter over quarter to €187 million and full‑year sales reaching €477 million. More than 5,300 U.S. patients have now been prescribed the drug by roughly 2,400 prescribers, with an approval rate around 70% and launches or named‑patient access in over 30 countries.
Skytrofa solid commercial performance
Skytrofa contributed another leg of growth, posting €53 million in Q4 and €206 million for 2025 while capturing about 7% of the U.S. growth hormone market. Ascendis has kicked off a Phase III basket trial in multiple pediatric indications, targeting segments that together could represent up to half of the overall growth hormone market.
Company revenue, cash and operating cash flow
Total Q4 revenue reached €248 million, bringing full‑year 2025 revenue to €720 million, supported by €7 million in collaboration income. Cash and cash equivalents climbed to €616 million from €560 million a year earlier, and Q4 operating cash flow of €73 million underscored improving cash generation.
Pipeline and regulatory momentum
On the R&D side, TransCon CNP is under U.S. review with a decision expected in early 2026, backed by Phase II data showing three to four times better linear growth than monotherapy and favorable body proportionality results. Ascendis is also progressing once‑weekly TransCon PTH and advancing strategic partnerships such as its collaboration on a once‑monthly semaglutide program.
Ambitious financial outlook
Management laid out an aggressive growth plan, targeting around €500 million in operating cash flow in 2026 and aspiring to at least €5 billion in annual product revenue by 2030. The company sees continued strong momentum from Yorvipath and a steady, seasonal pattern for Skytrofa as key drivers, with the broader pipeline expected to layer on additional growth over time.
Operating expenses exceed full-year revenue
Despite revenue gains, full‑year 2025 operating expenses rose to €761 million, surpassing revenue by about €41 million and highlighting a heavy investment phase. Fourth‑quarter operating expenses of €214 million point to a high run rate that management says it will watch closely as it balances growth initiatives with profitability.
Large noncash finance remeasurement loss
Below the operating line, reported earnings were hit by a €106 million noncash remeasurement loss on financial liabilities, driving net noncash finance expense to €93 million. The company stressed that actual net cash finance expense was modest at around €8 million, framing the accounting impact as largely optical rather than a drain on liquidity.
Currency headwinds reduced reported revenue
Foreign‑exchange moves were another drag, with a weaker U.S. dollar shaving roughly €27 million from Yorvipath revenue and €9 million from Skytrofa. Management underscored that underlying demand trends remain strong, suggesting that the roughly €36 million FX impact understates the true operational performance of the franchises.
U.S. penetration and access still early
Even with strong adoption metrics, Ascendis estimates that less than 5% of the U.S. patient pool is currently on Yorvipath, leaving substantial headroom for growth if access improves. Insurance approvals at about 70% and varied reimbursement dynamics outside the U.S. mean that market expansion will likely be uneven and subject to seasonal and quarterly volatility.
Competitive and clinical uncertainties
Management acknowledged a growing competitive field, including encaleret, FGFR inhibitors, and other long‑acting CNP candidates that could pressure future share. Executives also flagged potential safety concerns around nonspecific FGFR inhibitors, underscoring that evolving efficacy and safety profiles across the class will be closely watched by prescribers and investors.
Near-term guidance exclusions and launch uncertainty
The company excluded TransCon CNP from its 2026 outlook until regulatory outcomes are known, leaving a near‑term gap in visibility around launch costs and early revenue. Management also cautioned that seasonal patterns, especially in the first quarter, and initial investment needs could introduce choppiness in reported numbers even if long‑term adoption proves strong.
Forward-looking guidance and management expectations
Looking ahead, Ascendis is guiding to around €500 million in operating cash flow for 2026 while reiterating its ambition to reach at least €5 billion in annual product revenue by 2030. Executives expect Yorvipath to remain the primary growth engine in 2026, with Skytrofa following its established seasonal curve and potential upside from TransCon CNP not yet reflected in official forecasts.
Ascendis Pharma’s earnings call painted a picture of a company in high‑growth investment mode, trading near‑term margin pressure for expanded market reach and pipeline depth. For investors, the central question is whether booming franchise sales and advancing late‑stage assets can ultimately outpace rising costs, currency noise, and competitive risk to unlock the long‑term earnings power management is targeting.
